Influence of Atherosclerosis-Associated Risk Factors on Expression of Endothelin Receptors in Advanced

Oliver Herbers1, Carsten Höltke1, Marco Virgilio Usai2

  • 1Clinic for Radiology, University Hospital Münster, 48149 Münster, Germany.

Insights

Endothelin receptor expression decreases in atherosclerosis, particularly with hypertension. This study clarifies endothelin receptor roles in atherosclerosis pathogenesis and risk factors.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Vascular Pathology

Background:

  • Endothelin-1 (ET-1) is implicated in atherosclerosis, but endothelin receptor (ETAR, ETBR) roles are unclear.
  • Understanding ET receptor expression in advanced atherosclerotic plaques is crucial for elucidating their role in disease progression.

Purpose of the Study:

  • To investigate endothelin receptor expression in human atherosclerotic plaques.
  • To correlate ET receptor expression with atherosclerosis risk factors.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) analysis of 98 atherosclerotic plaques and controls.
  • Linear regression models to analyze correlations with risk factors like hypertension, age, BMI, and gender.

Main Results:

  • Reduced expression of ETAR, ETBR, and smooth muscle actin (SMA) in atherosclerotic plaques.
  • ET-1 and matrix metalloproteinase 2 (MMP-2) levels remained unchanged.
  • Reduced receptor and SMA expression strongly correlated with hypertension, age, BMI, and gender, but not diabetes or smoking.

Conclusions:

  • Endothelin receptor expression in atherosclerosis is primarily linked to hypertension.
  • Hypertension significantly influences ET receptor and SMA expression in advanced plaques.
  • Diabetes and smoking appear to have ancillary roles in ET receptor expression during atherosclerosis.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
121
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
564
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
439
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.5K